Pharmacokinetic evaluation of fosaprepitant dimeglumine

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 10, 2010, Pages 1277-1286

  Colon Gonzalez, Francheska ^a   Kraft, Walter K ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Aprepitant; Chemotherapy induced nausea and vomiting; Emesis; Fosaprepitant; Neurokinin 1 receptor antagonist

Indexed keywords

3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; ANTHRACYCLINE; APREPITANT; CASOPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; FOSAPREPITANT; L 785298; METHYLPREDNISOLONE; MIDAZOLAM; NAVELBINE; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; PALONOSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; TOLBUTAMIDE; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL PAIN; ANOREXIA; ASTHENIA; BREAST CANCER; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HICCUP; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NAUSEA AND VOMITING; NEOPLASM; NONHUMAN; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; POSTOPERATIVE NAUSEA AND VOMITING; QT PROLONGATION; REVIEW; SINGLE DRUG DOSE; VOMITING;

ANIMALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; HUMANS; MORPHOLINES; NAUSEA; NEOPLASMS; PRODRUGS; RECEPTORS, NEUROKININ-1; THERAPEUTIC EQUIVALENCY; VOMITING;

EID: 77956818697     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.513970     Document Type: Review

References (36)

1. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol 2006;24(18):2932-2947
2. Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009;69(13):1853-1878
3. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 2007;12(9):1143-1150
4. NCCN Clinical Practice Guidelines in Oncology: Antiemesis V.2.2010; 2010. Available from: http://www.nccn. org/professionals/physician-gls/PDF/ antiemesis.pdf [Cited 10 July 2010]
5. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17(1):20-28
6. Le TP, Gan TJ. Update on the management of postoperative nausea and vomiting and postdischarge nausea and vomiting in ambulatory surgery. Anesthesiol Clin 2010;28(2):225-249
7. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97(12):3090-3098
8. Merck & Co., Inc. Emend (fosaprepitant dimeglumine) for injection. White House Station, NJ, USA; 2008
9. Prommer E. Aprepitant (EMEND): the role of substance P in nausea and vomiting. J Pain Palliat Care Pharmacother 2005;19(3):31-39
10. Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 2002;63(Suppl 11):18-24
11. Tattersall FD, Rycroft W, Hargreaves RJ, Hill RG. The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 1993;250(1):R5-6
12. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21(22):4112-4119
13. Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006;14(4):354-360
14. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17(6):1000-1006
15. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23(12):2822-2830
16. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21(Suppl 5):v232-43
17. BC Cancer Agency - SCNAUSEA Protocol: British Columbia Cancer Agency; 2009
18. EMEA. Questions and answers on the withdrawal of the marketing authorisation application for Zunrisa: casopitant; 2009
19. GSK. Regulatory update for REZONICTM (casopitant mesylate); 2009
20. ClinicalTrials.gov; 2010. Available from: http://clinicaltrials.gov/ct2/ results? term=casopitant [Cited 29 May 2010]
21. Hale JJ, Mills SG, MacCoss M, et al. Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J Med Chem 2000;43(6):1234-1241
22. Huskey S-EW, Luffer-Atlas D, Dean BJ, et al. Substance P receptor antagonist I: conversion of phosphoramidate prodrug after i.v. Administration to rats and dogs. Drug Metab Dispos 1999;27(11):1367-1373
23. Lasseter KC, Gambale J, Jin B, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 2007;47(7):834-840
24. Majumdar AK, Howard L, Goldberg MR, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 2006;46(3):291-300
25. Depre M, Van Hecken A, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005;61(5-6):341-346
26. Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001;37(7):835-842
27. Simon VB, Michael RL, Rudolph MN, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002;94(11):3032-3041
28. FDA. Code of Federal Regulations Title 21; 2009:21CFR320.1
29. Grunberg SM, Chua DT, Maru A, et al. Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 2010;28:15s (Suppl; abstr 9021)
30. ClinicalTrials.gov; 2010. Available from: http://clinicaltrials.gov/ct2/ results? term=fosaprepitant [Cited 18 April 2010]
31. Kesisoglou F, Panmai S, Wu Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007;59(7):631-644
32. Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 2008;3(3):295-309
33. Marbury TC, Jin B, Panebianco D, et al. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects. Anesth Analg 2009;109(2):418-425
34. Herrstedt J, Roila F. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2009;20(Suppl 4):iv156-8
35. Munoz M, Rosso M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 2010;28(2):187-193
36. Moore S, Tumeh J, Wojtanowski S, Flowers C. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health 2007;10(1):23-31